Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery

Current Medical Research and Opinion

Volumn 27, Issue 11, 2011, Pages 2123-2131

  Martin, Michelle T ^a   Nutescu, Edith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anticoagulant; Apixaban; Direct factor Xa inhibitor; TKA

Indexed keywords

APIXABAN; BETRIXABAN; DABIGATRAN; DAREXABAN; EDOXABAN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; SEMULOPARIN; WARFARIN;

ANTICOAGULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOW DRUG DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; CLINICAL TRIALS AS TOPIC; EUROPEAN UNION; HUMANS; PYRAZOLES; PYRIDONES; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 80054692527     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.619178     Document Type: Review

References (33)

1. Geerts WH, Bergquist D, Pineo GF, et al. Prevention of venous thromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133:381S-453S (Pubitemid 351894916)
2. European Medicines Agency. Committee for Medicinal Products for Human Use Summary of Opinion. March 17, 2011. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial authorisation/human/002148/WC500103875.pdf [Last accessed 11 July 2011]
3. Pharm Info website. Available at: http://pharminfo.co.cc/2010/10/ bmsinitiated-apixaban-filing-for-fda-approval/#more-2812 [Last accessed 11 April 2011]
4. Drug Info Pipeline website. Available at: http://www. drugpipelineforecast. com/pipeline/product.html?id1/4236305df-8506-4392-8657- eb37d26cd8b9-Eliquis-apixaban [Last accessed 11 July 2011]
5. Press release. Available at: http://www.jnjpharmarnd.com/jnjpharmarnd/ assets/Rivaroxaban-Filing%20for%20SPAF%20Press%20ReleasËFINAL. pdf#zoom1/4100 [Last accessed 11 April 2011]
6. Bayer website. Rivaroxaban. Available at: http://www.bayer.com/en/ bayerhealthcare. aspx [Last accessed 11 April 2011]
7. Betrixaban News Release. Available at: http://www.portola.com/pdfs/ Betrixaban-Release.pdf [Last accessed 11 April 2011]
8. Astellas News Release. Available at: http://www.astellas.com/en/ corporate/news/pdf/110215-eg.pdf [Last accessed 11 April 2011]
9. Daiichi Sankyo News Release. Available at: http://www.daiichisankyo.com/ news/detail/004033.html [Last accessed 30 April 2011]
10. FDA News Release. Dabigatran. Available at: http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm230241.htm [Last accessed 11 April 2011]
11. Turpie AG, Bauer KA, Davidson BL, et al. for the EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101:68-76
12. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RËMODEL randomized trial. J Thromb Hemost 2007;5:2178-85 (Pubitemid 47617868)
13. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24:1-9
14. ClinicalTrials.gov. Phase II/III Study of YM150-A Placebo-controlled, Doubleblind, Group Comparison Study in Patients Undergoing Elective Total Knee Replacement Surgery. Available at: http://clinicaltrials.gov/ct2/show/ NCT00917254?term1/4ym150&rank1/410 [Last accessed 11 April 2011]
15. ClinicalTrials.gov. A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial). Available at: http://clinicaltrials. gov/ct2/show/NCT01181102?term1/4 edoxaban&rank1/43 [Last accessed 11 April 2011]
16. Fuji T, et al. Edoxaban versus enoxaparin for thromboprophylaxis after total knee replacement: The STARS E-3 trial. 21st International Congress of Thrombosis, July 6-9 2010, Milano, Italy
17. Lassen MR, Ageno W, Borris LC, et al. for the RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86 (Pubitemid 351930852)
18. Turpie AG, Lassen MR, Davidson BL, et al. for the RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80
19. Lassen MR, Dahl OE, Mismetti P, et al. AVE5026, a new hemisynthetic ultralow-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery-TREK: a dose-ranging study. J Thromb Haemost 2009;7:566-72
20. ClinicalTrials.gov. A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery. Available at: http://clinicaltrials.gov/ct2/show/ NCT00718224 [Last accessed 11 April 2011]
21. Lu G, DeGuzman FR, Lakhotia S, et al. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors [abstract]. Blood 2008;112(11): Abstract 983
22. Wong PC, Crain EJ, Xin RR, et al. Apixaban, an oral direct and highly selective factor Xa inhibitor: in vitro antithrombotic and antihemostatic studies. J Thromb Haemost 2007;6:820-9 (Pubitemid 351524543)
23. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37: 74-81
24. Zhang D, He K, Raghavan N, et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 2009;37:1738-48
25. Stangier J, Rathgen K. Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303 (Pubitemid 47283865)
26. Dabigatran (Pradaxa) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2011. Available at: http://bidocs. boehringeringelheim. com/BIWebAccess/ViewServlet.ser?docBase1/ 4renetnt&folderPath1/4/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf [Last accessed 9 April 2011]
27. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61:873-80 (Pubitemid 41803696)
28. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22
29. Becattini C, Lignani A, Agnelli G. New anticoagulants for the prevention of venous thromboembolism. Drug Des Devel Ther 2010;4:49-60
30. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007;5:2368-75 (Pubitemid 350154345)
31. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
32. Lassen MR, Raskob GE, Gallus A, et al. for the ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375:807-15
33. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4 (Pubitemid 41647882)